Ptc Therapeutics, Inc.

Nadiya Sydorenko

Young-Choon Moon

Anuradha Bhattacharyya

Suresh D Babu

Ramil Y Baiazitov

Steven David Paget

Hongyu Ren

Chang-Sun Lee

Wu Du

Seongwoo Hwang

Richard Gerald Wilde

Jana Narasimhan

Matthew G Woll

Minakshi B Jani

Gary Mitchell Karp

Liangxian Cao

Nanjing Zhang

Anthony A Turpoff

Thomas W Davis

Jigar S Patel

Anthony R Mazzotti

Ronggang Liu

Guangming Chen

Scott J Barraza

Minakshi Jani

Zhenrong Xu

Soongyu Choi

Xiaoyan Zhang

Andrew Kassick

Wuming Yan

Md Rauful Alam

Suresh Babu

Aleksey I Gerasyuto

Michael Andrew Arnold

Lukiana Amedzo

Christie Morrill

Daniel J Medina

Hiroo Koyama

Tom Tuan Luong

Anthony Turpoff

Marites A Rafanan

Nicholas W Mszar

Sudipta Pal

Nathaniel T Kenton

Nicholas Walter Mszar

Gang Wang

Steven D Paget

Ramil Baiazitov

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted benzothiazole compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Heteroaryl compounds for treating Huntington's disease

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Compounds for treating huntington's disease

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Heterocyclic and heteroaryl compounds for treating Huntington's disease

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Compounds for treating Huntington's disease

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.  In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Methods for treating Huntington's disease

The present description relates to a method or use of a compound for treating or ameliorating HD (Huntington's Disease) in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I): or a form thereof, wherein w, w, w, w, w, wand ware as defined herein. In particular, the present description relates to a method of use of a compound of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering an effective amount of the compound or a form or composition thereof to the subject.

Methods for treating Huntington's Disease

Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Substituted reverse pyrimidine Bmi-1 inhibitors

Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Substituted pyridine and pyrazine BMI-1 inhibitors

Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Substituted pyrimidine Bmi-1 inhibitors

Amine substituted triazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Substituted triazine BMI-1 inhibitors

Compounds having Formula I: wherein the variables Ar, Ar, R, Rand Rare defined herein, pharmaceutical compositions, and methods of using such compounds or compositions for inhibiting Bmi-1 expression.

BMI-1 protein expression modulators

Growing community of inventors

Princeton, NJ, United States of America

Nadiya Sydorenko